Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | IKBKB | O14920 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704326 | 0.93 | IKBKB (0.36) | IKBKBKDM4EALDH1A1 | |
| SCHEMBL1704477 | 0.90 | FPR2 (0.35) | FPR2KDM4EALDH1A1 | |
| SCHEMBL2329098 | 0.86 | MAPK14 (0.34) | MAPK14IKBKBKDM4EGRM2 | |
| SCHEMBL2131687 | 0.86 | FPR2 (0.39) | IKBKBFPR2KDM4E | |
| SCHEMBL1704456 | 0.85 | IKBKB (0.41) | IKBKBFPR2 | |
| SCHEMBL1703783 | 0.84 | LRRK2 (0.35) | FPR2 | |
| SCHEMBL1704159 | 0.84 | IKBKB (0.44) | IKBKBFPR2KDM4EALDH1A1HPGD | |
| SCHEMBL1703858 | 0.82 | RAB9A (0.33) | MAPK14IKBKBFPR2KDM4E | |
| SCHEMBL2331664 | 0.80 | MAPK14 (0.34) | MAPK14IKBKB | |
| SCHEMBL2332145 | 0.78 | MMP1 (0.38) | MAPK14IKBKBKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | claimed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | claimed |
| US-8580831-B2 | Fluorinated aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
| EP-2440555-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101138-A1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | AFF1, SULT2A1, NAT1 | MAPK14 4246/4885IKBKB 4277/4885FPR2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.